IP Library › Granted Patent US 12,357,565
Granted Patent B2
US 12,357,565 · App. 17/991,762 · Granted Jul 15, 2025

Ocular implant containing a tyrosine kinase inhibitor

Inventors: Charles D. Blizzard (Nashua, NH); Arthur Driscoll (Reading, MA); Rami El-Hayek (Norwood, MA); Michael Goldstein (Cambridge, MA); Joseph Iacona (Somerville, MA); Peter Jarrett (Burlington, MA); Timothy S. Jarrett (Boston, MA); Erica Kahn (Cambridge, MA); Zachary Lattrell (Newburyport, MA)
Assignee: OCULAR THERAPEUTIX, INC.
A61K9/0051A61K9/06A61K31/4427A61K31/4439A61K47/34A61P27/02A61K9/0019A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,357,565
App. No.
17/991,762
Granted
Jul 15, 2025
Kind
B2
Abstract

The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.

Claims (10)

1. A method of manufacturing a sustained release biodegradable ocular implant comprising forming a hydrogel comprising tyrosine kinase inhibitor particles dispersed within the hydrogel, shaping the hydrogel, and drying the hydrogel, wherein the implant in its dry state has a length of about 6 mm to about 17 mm and a diameter of 0.1 mm to 0.5 mm; and has a total implant weight of about 0.2 mg to about 1.5 mg, wherein the ocular implant is not created in situ.

2. The method of claim 1 , wherein the shaping comprises forming the hydrogel into a hydrogel strand.

3. The method of claim 2 , further comprising stretching the hydrogel strand.

4. The method of claim 3 , wherein the stretching is in a longitudinal direction.

5. The method of claim 4 , wherein the stretch factor is from above 1 to about 4.

6. The method of claim 2 , further comprising cutting the strand into segments.

7. The method of claim 1 , wherein the tyrosine kinase inhibitor is axitinib.

8. The method of claim 6 , wherein the tyrosine kinase inhibitor is axitinib and each segment comprises an amount of axitinib from about 150 μg to about 1200 μg.

9. The method of claim 1 , wherein the hydrogel comprises a polymer network.

10. The method of claim 9 , wherein the polymer network is formed by mixing and reacting an electrophilic group-containing multi-arm PEG precursor with a nucleophilic group-containing multi-arm PEG precursor or another nucleophilic group-containing crosslinking agent in a buffered solution in the presence of the tyrosine kinase inhibitor and allowing the mixture to gel to form the hydrogel.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2024
From: BLIZZARD, CHARLES D.; DRISCOLL, ARTHUR; EL-HAYEK, RAMI; GOLDSTEIN, MICHAEL; IACONA, JOSEPH; JARRETT, PETER; JARRETT, TIMOTHY S.; KAHN, ERICA; LATTRELL, ZACHARY
To: OCULAR THERAPEUTIX, INC.
Reel/Frame 068365/0558 →
Continuity (6)
Continuation 17744189 · May 13, 2022
Continuation 17210696 · Mar 24, 2021
Provisional Application 63148463 · Feb 11, 2021
Provisional Application 63106276 · Oct 27, 2020
Provisional Application 62994391 · Mar 25, 2020
Related Publication 20230118774A1 · Apr 20, 2023
References Cited (152)
US 3949750A · Freeman · 1976 [cited by applicant]
US 3993071A · Higuchi et al. · 1976 [cited by applicant]
US 4915684A · MacKeen et al. · 1990 [cited by applicant]
US 5469867A · Schmitt · 1995 [cited by applicant]
US 5902598A · Chen et al. · 1999 [cited by applicant]
US 6027470A · Mendius · 2000 [cited by applicant]
US 6196993B1 · Cohan et al. · 2001 [cited by applicant]
US 6509327B1 · Cagle et al. · 2003 [cited by applicant]
US 6534524B1 · Kania et al. · 2003 [cited by applicant]
US 6646001B2 · Hellberg et al. · 2003 [cited by applicant]
US 6726918B1 · Wong et al. · 2004 [cited by applicant]
US 6899717B2 · Weber et al. · 2005 [cited by applicant]
US 6982090B2 · Gillespie · 2006 [cited by applicant]
US 7090681B2 · Weber et al. · 2006 [cited by applicant]
US 7998497B2 · de Juan, Jr. et al. · 2011 [cited by applicant]
US 8034366B2 · Shiah et al. · 2011 [cited by applicant]
US 8034370B2 · Shiah et al. · 2011 [cited by applicant]
US 8039470B2 · Liang et al. · 2011 [cited by applicant]
US 8409606B2 · Sawhney et al. · 2013 [cited by applicant]
US 8506987B2 · Shiah et al. · 2013 [cited by applicant]
US 8512738B2 · Hughes et al. · 2013 [cited by applicant]
US 8512749B2 · Edelman et al. · 2013 [cited by applicant]
US 8524709B2 · Liang et al. · 2013 [cited by applicant]
US 8535705B2 · Edelman et al. · 2013 [cited by applicant]
US 8563027B2 · Sawhney et al. · 2013 [cited by applicant]
US 8685435B2 · Nivaggioli et al. · 2014 [cited by applicant]
US 8791140B2 · Campeta et al. · 2014 [cited by applicant]
US 8956655B2 · Lyons et al. · 2015 [cited by applicant]
US 8961501B2 · Jarrett et al. · 2015 [cited by applicant]
US 9125807B2 · Sawhney et al. · 2015 [cited by applicant]
US 9192511B2 · Shiah et al. · 2015 [cited by applicant]
US 9205150B2 · El-Hayek et al. · 2015 [cited by applicant]
US 9254267B2 · Sawhney · 2016 [cited by applicant]
US 9278139B2 · Rau et al. · 2016 [cited by applicant]
US 9320647B2 · Lerner et al. · 2016 [cited by applicant]
US 9370485B2 · Sawhney et al. · 2016 [cited by applicant]
US 9447469B2 · Lamont · 2016 [cited by applicant]
US 9463114B2 · Odrich et al. · 2016 [cited by applicant]
US 9504653B2 · Liu et al. · 2016 [cited by applicant]
US 9539259B2 · Zack et al. · 2017 [cited by applicant]
US 9572800B2 · Zarnitsyn et al. · 2017 [cited by applicant]
US 9636189B2 · Ahari et al. · 2017 [cited by applicant]
US 9775906B2 · Sawhney et al. · 2017 [cited by applicant]
US 9849082B2 · de Juan, Jr. et al. · 2017 [cited by applicant]
US 9931330B2 · Zarnitsyn et al. · 2018 [cited by applicant]
US 9980901B2 · Ni · 2018 [cited by applicant]
US 10010610B2 · Horn · 2018 [cited by applicant]
US 10076526B2 · Shiah et al. · 2018 [cited by applicant]
US 10111886B2 · Ng et al. · 2018 [cited by applicant]
US 10119202B2 · Mao et al. · 2018 [cited by applicant]
US 10226417B2 · Jarrett et al. · 2019 [cited by applicant]
US 10251954B2 · Sawhney et al. · 2019 [cited by applicant]
US 10300014B2 · de Juan, Jr. et al. · 2019 [cited by applicant]
US 10420724B2 · Jarrett et al. · 2019 [cited by applicant]
US 10570202B2 · Martini et al. · 2020 [cited by applicant]
US 10617563B2 · Jarrett et al. · 2020 [cited by applicant]
US 10688092B2 · Ni et al. · 2020 [cited by applicant]
US 10702539B2 · Shiah et al. · 2020 [cited by applicant]
US 10786462B2 · Jarrett et al. · 2020 [cited by applicant]
US 10869924B2 · Andrews et al. · 2020 [cited by applicant]
US 10874605B2 · Nivaggioli et al. · 2020 [cited by applicant]
US 10874606B2 · de Juan, Jr. et al. · 2020 [cited by applicant]
US 10905765B2 · Jarrett et al. · 2021 [cited by applicant]
US 11053224B2 · Liang et al. · 2021 [cited by applicant]
US 11129690B2 · Fisher · 2021 [cited by applicant]
US 11439592B2 · Blizzard · 2022 [cited by examiner]
US 11534396B2 · Blizzard · 2022 [cited by examiner]
US 20020169409A1 · Gillespie · 2002 [cited by applicant]
US 20030065060A1 · Qvist et al. · 2003 [cited by applicant]
US 20030108511A1 · Sawhney · 2003 [cited by applicant]
US 20040175410A1 · Ashton et al. · 2004 [cited by applicant]
US 20050197614A1 · Pritchard et al. · 2005 [cited by applicant]
US 20050232972A1 · Odrich · 2005 [cited by applicant]
US 20050244475A1 · Edelman et al. · 2005 [cited by applicant]
US 20050283109A1 · Peyman · 2005 [cited by applicant]
US 20060095108A1 · Chowdhury et al. · 2006 [cited by applicant]
US 20070298075A1 · Borgia et al. · 2007 [cited by applicant]
US 20080124400A1 · Liggins et al. · 2008 [cited by applicant]
US 20080140192A1 · Humayun et al. · 2008 [cited by applicant]
US 20080247984A1 · Messersmith et al. · 2008 [cited by applicant]
US 20090227981A1 · Bennett · 2009 [cited by applicant]
US 20120059338A1 · Beeley et al. · 2012 [cited by applicant]
US 20120156259A1 · Rau et al. · 2012 [cited by applicant]
US 20140128478A1 · Asgharian et al. · 2014 [cited by applicant]
US 20150037422A1 · Kaplan et al. · 2015 [cited by applicant]
US 20160296627A1 · Garcia et al. · 2016 [cited by applicant]
US 20160331738A1 · Jarrett · 2016 [cited by examiner]
US 20170182173A1 · Ng et al. · 2017 [cited by applicant]
US 20180085307A1 · Sawhney et al. · 2018 [cited by applicant]
US 20180353431A1 · Guo et al. · 2018 [cited by applicant]
US 20190070339A1 · Gerecht et al. · 2019 [cited by applicant]
US 20190336441A1 · Whitcup et al. · 2019 [cited by applicant]
US 20190388522A1 · Burian et al. · 2019 [cited by applicant]
US 20200306182A1 · Das et al. · 2020 [cited by applicant]
US 20200337989A1 · Jarrett et al. · 2020 [cited by applicant]
US 20210007973A1 · Patel et al. · 2021 [cited by applicant]
US 20210017266A1 · Racine et al. · 2021 [cited by applicant]
US 20220054476A1 · Rosen et al. · 2022 [cited by applicant]
US 20220054477A1 · Rosen et al. · 2022 [cited by applicant]
US 20220054478A1 · Rosen et al. · 2022 [cited by applicant]
US 20220062273A1 · Sprogøe et al. · 2022 [cited by applicant]
US 20220080044A1 · Chen et al. · 2022 [cited by applicant]
US 20230116809A1 · Knappe et al. · 2023 [cited by applicant]
US 20230140691A1 · Byrne et al. · 2023 [cited by applicant]
US 20230302156A1 · Jiang et al. · 2023 [cited by applicant]
US 20230338286A1 · Bassett et al. · 2023 [cited by applicant]
CN 104884049A · 2015 [cited by applicant]
CN 107205922A · 2017 [cited by applicant]
CN 109982683A · 2019 [cited by applicant]
CN 116419755A · 2023 [cited by applicant]
WO 0243785A2 · 2002 [cited by applicant]
WO 2009008946 · 2009 [cited by applicant]
WO 2010093873 · 2010 [cited by applicant]
WO 2010111449A1 · 2010 [cited by applicant]
WO 2013039706A1 · 2013 [cited by applicant]
WO 2013086015 · 2013 [cited by applicant]
WO 2013188273A1 · 2013 [cited by applicant]
WO 2016094646 · 2016 [cited by applicant]
WO 2016183296 · 2016 [cited by applicant]
WO 2017015591 · 2017 [cited by applicant]
WO 2017015616A1 · 2017 [cited by applicant]
WO 2017091749 · 2017 [cited by applicant]
WO 2018058048 · 2018 [cited by applicant]
WO 2019094652A1 · 2019 [cited by applicant]
WO 2020219890A1 · 2020 [cited by applicant]
WO 2020243608A1 · 2020 [cited by applicant]
International Search Report for PCT/US2021/023806 mailed Jul. 9, 2021, 4 pages. [cited by applicant]
Written Opinion of the International Searching Authority for PCT/US2021/023806 mailed Jul. 9, 2021, 9 pages [cited by applicant]
Narvekar et al., “Axitinib-Loaded Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Age-Related Macular Degeneration: Formulation development and In Vitro Characterization”, ASSAY and Druge Development Technologies, May/J… [cited by applicant]
Das, et al., “A review of emerging tyrosine kinase inhibitors as durable treatment of neovascular age-related mascular degeneration”, Expert Opinion on Emerging Drugs, 2023, 9 pgs. [cited by applicant]
Mattessich, et al., “Transforming Drug Delivery Leveraging a Novel Technology Platform,” Oct. 10, 2020. [cited by applicant]
El-Hayek, et al., “Efficacy of a 6 moth Sustained Hydrogel Delivery System for Tyrosine Kinase Inhibitors in a VEGF Induced Retinal Leakage Model,” Association for Research in Vision and Ophthalmology 2017 Annual Meetin… [cited by applicant]
Jarrett, P., et al., “Tolerability of a 6 month Sustained Hydrogel Delivery System for Tyrosine Kinase Inhibitors in Dutch Belted Rabbits,” Association for Research in Vision and Ophthamology 2017 Annual Meeting; Baltim… [cited by applicant]
Jarrett, T., et al., “Pharmacokinetics of a 6 month Sustained Hydrogel Delivery System for Tyrosine Kinase Inhibitors in Dutch Belted Rabbits,” Association for Research in Vision and Ophthamology 2017 Annual Meeting; Ba… [cited by applicant]
El-Hayek, et al., “Effectiveness of Sustained release TKI Hydrogel Combined with Bevacizumab in a VEGF Induced Retinal Leakage Model Through 12 Months,” Association for Research in Vision and Ophthalmology 2018 Annual M… [cited by applicant]
Jarrett, P, et al., “Efficacy and Tolerability of OTX-TKI, a Sustained Hydrogel Delivery System for a Tyrosine Kinase Inhibitor, in a VEGF-Induced Retinal Leakage Model through 12 Months,” presented at the ARVO Annual M… [cited by applicant]
Jarrett, P., et al., “Efficacy & Tolerability of OTX-TKI, a Sustained Hydrogel Delivery System for a Tyrosine Kinase Inhibitor, in a VEGF Induced Retinal Leakage Model: 1 Year Results,” Association for Research in Visio… [cited by applicant]
Csaky, et al., “Evaluating safety, tolerability and biological activity of OTX-TKI, a hydrogel-based, sustained-release Intravitreal axitinib implant, in subjects with neovascular age-releated mascular degeneraiton (nAM… [cited by applicant]
Ocular TTherapeutix™ Reports Second Quarter 2020 Financial Results and Business Update, Newly Published Physician Fee Schedules for 0356T for the Administration of Intracanalicular Inserts to Support Ongoing DEXTENZA® L… [cited by applicant]
Kim et al., “Persistent Remnants of Dexamethasone Intravitreal Implant (Ozurdex)”, Retina, The Journal of Retinal and Vitreous Diseases, vol. 00, No. 00, Feb. 13, 2020, pp. 1-6, published by Retina. [cited by applicant]
Gillies et al., “A Randomized Clinical Trial of Intravitreal Bevacizumab versus Intravitreal Dexamethasone for Diabetic Macular Edema”, Opthamology, vol. 121, No. 12, Dec. 2014, pp. 2473-2481, published by American Acad… [cited by applicant]
Bacharach et al., “Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)”, Drugs, vol. 81 No. 17, pp. 2017-2033, p… [cited by applicant]
Rahic et al., “Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions”, Pharmaceutics, vol. 13, No. 28, pp. 1-58, published by MDPI. [cited by applicant]
Pardo-Lopez et al., “Anterior chamber migration of dexametasona intravitreal implant (Ozurdex)”, Graefe's Archive for Clinical and Experimental Opthalmology, Nov. 2011, vol. 250, pp. 1703-1704, Published by Springer. [cited by applicant]
European Search Report for Application No. 21164737.5 dated Aug. 18, 2021, 4 pgs. [cited by applicant]
Avery, et al., “Preliminary Findings from a Phase 1 Trial Evaluating the Safety, Tolerability and Biological Activity of OTX-TKI, a Hydrogel-Based, Sustained-Release Intravitreal Axitinib Implant, in Subjects with Neova… [cited by applicant]
Avery, Robert L., “Safety and Efficacy of OTX-TKI, a Novel Tyrosine Kinase Inhibitor Hydrogel Intravitreal Implant,” Annual VIT Buckle Society Meeting, Apr. 2020. [cited by applicant]
Csaky, et al., “Evaluating Safety, Tolerability and Biological Activity of OTX-TKI, a Hydrogel-Based, Sustained-Relese Intravitreal Axitinib Implant, in Subjects with Neovascular Age-Releated Macular Degeneration Prelim… [cited by applicant]
Mattessich, et al., “Transforming Drug Delivery Leveraging a Novel Technology Platform,” Sep. 2020. [cited by applicant]
Bao, Zhi et al., “Preparation of axitnib in biodegradable drug membranes for ocular surface”, Chin J. Clin. Pharmacol, vol. 33, No. 17, Sep. 2017, 4 pages. [cited by applicant]
Kahn, Erica et al., “A Safety and Pharmacokinetic Study of a Novel Hydrogel-based Axitnib Intravitreal Implant (OTX-TKI) in Non-Human Primates”, Investigative Ophthamology & Visual Science, Jun. 2022, vol. 63, 4 pages. [cited by applicant]
Giddabasappa et al., “Axitinib inhibits retinal and choroidal neovascularization in in vitro and in vivo models”, Experimental Eye Research, 2016, pp. 373-379. vol. 145, Elsevier. [cited by applicant]
Cited By (1)
US 12,453,724